BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TQB2934 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TQB2934\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07179679-3389@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:TQB2934: Phase 1 readout est. (NCT07179679)
DESCRIPTION:TQB2934\, phase 1\, Multiple Myeloma.\nStudy: A Clinical Study 
 Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subject
 s With Malignant Plasma Cell Tumors\nEstimated primary completion: October
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/tqb2934#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07179679
URL:https://assetmemo.bio/drug/tqb2934#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07569757-3389@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:TQB2934: Phase 3 readout est. (NCT07569757)
DESCRIPTION:TQB2934\, phase 3\, Multiple Myeloma.\nStudy: Clinical Study of
  TQB2934 Injection in Relapsed/Refractory Multiple Myeloma\nEstimated prim
 ary completion: December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tqb2934#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07569757
URL:https://assetmemo.bio/drug/tqb2934#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266116-3389@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:TQB2934: Phase 1/2 readout est. (NCT07266116)
DESCRIPTION:TQB2934\, phase 1/2.\nStudy: Assessment of the Efficacy and Saf
 ety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain
  Amyloidosis Patients\nEstimated primary completion: February 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tqb2934#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07266116
URL:https://assetmemo.bio/drug/tqb2934#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
